Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Net Cash Flow: 2010-2025

Historic Net Cash Flow for Heron Therapeutics (HRTX) over the last 12 years, with Sep 2025 value amounting to $26.6 million.

  • Heron Therapeutics' Net Cash Flow rose 261.01% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 290.03%. This contributed to the annual value of -$2.9 million for FY2024, which is 121.60% down from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Net Cash Flow is $26.6 million, which was up 1,064.48% from -$2.8 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Net Cash Flow high stood at $131.4 million for Q2 2021, and its period low was -$69.0 million during Q4 2021.
  • Moreover, its 3-year median value for Net Cash Flow was -$2.1 million (2024), whereas its average is $2.5 million.
  • In the last 5 years, Heron Therapeutics' Net Cash Flow slumped by 790.50% in 2021 and then soared by 1,069.87% in 2023.
  • Over the past 5 years, Heron Therapeutics' Net Cash Flow (Quarterly) stood at -$69.0 million in 2021, then spiked by 49.19% to -$35.1 million in 2022, then spiked by 82.37% to -$6.2 million in 2023, then soared by 100.99% to $61,000 in 2024, then surged by 261.01% to $26.6 million in 2025.
  • Its Net Cash Flow was $26.6 million in Q3 2025, compared to -$2.8 million in Q2 2025 and -$6.5 million in Q1 2025.